Effect of Jiangzhiligan Granules on CYP2E1 Gene and Protein Expression of Rat Model with Non-alcoholic Fatty Liver Disease

Abstract

Abstract: ObjectiveTo evaluate the effect of Jiangzhiligan granules on cytochrome P450 2E1 (CYP2E1) gene and protein expression of rat model with non-alcoholic fatty liver disease (NAFLD), and investigate the mechanism of the drug. MethodsSDF levels of 20 healthy Wistar rats were selected and established the NAFLD model. All of the rats were divided into the prevention group and model group by random number table method, with 10 in each group. Since the second week of model establishment; the rats in the prevention group were given Jiangzhiligan granules by gavage, 1 time daily, 6 g per kg body weight; while the model group was given equal amounts of normal saline by gavage; for 6 weeks in both of the two groups. The liver histopathology, liver function, serum lipid, oxidation indexes, levels of CYP2E1 mRNA and protein expression were compared between the two groups, and the effect of Jiangzhiligan granules on CYP2E1 gene and protein expression of rat model with NAFLD was summarized. ResultsThe liver wet weight and liver indexes of the prevention group were lower than those in model group, the difference was statistically significant (P < 0.05). There was no significant difference of body mass index between the two groups (P > 0.05). Partial steatosis of hepatocytes in the prevention group was found, and its steatotic degree was lower than that of the model group, the difference was statistically significant (P < 0.05). Compared with 2 weeks after model establishment, the AST, ALT, TC, TG, HDL-C, LDL-C, MDA in the prevention group decreased significantly, and the SOD, GSH-PX, GSH increased significantly than those before the end of the experiment, the difference was statistically significant (P < 0.05). Before the end of the experiment, the levels of CYP2E1 mRNA and protein expression of liver tissue in the prevention group were lower than those in the model group, the difference was statistically significant (P < 0.05).ConclusionJiangzhiligan granules could downgrade the CYP2E1 mRNA and protein in liver tissue of the rat model with NAFLD, and could improve the Liver function, blood lipid and oxidation index.

Key words: Jiangzhiligan granules, non-alcoholic fatty liver disease model, cytochrome P450 2E1

CLC Number:

R965

BIAN Xiao-lan, ZHAI Qing, YU Bo. Effect of Jiangzhiligan Granules on CYP2E1 Gene and Protein Expression of Rat Model with Non-alcoholic Fatty Liver Disease[J]. Chinese Journal of Pharmacovigilance, 2017, 14(1): 10-13.

References

[1] Leung T M, Nieto N. CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease[J]. Journal of hepatology, 2013, 58(2): 395-398.
[2] Leamy A K, Egnatchik R A, Young J D. Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease[J]. Progress in lipid research, 2013, 52(1): 165-174.
[3] 余辉, 段永强, 谢明, 等. 细胞色素 P4502E1 在大鼠非酒精性脂肪肝形成中的作用[J]. 中西医结合肝病杂志, 2015, 25(6): 349-351.
[4] Jump D B, Depner C M, Tripathy S, et al. Impact of dietary fat on the development of non-alcoholic fatty liver disease in Ldlr-/- mice[J]. Proceedings of the Nutrition Society, 2016, 75(1): 1-9.
[5] Begriche K, Massart J, Robin M A, et al. Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease[J]. Hepatology, 2013, 58(4): 1497-1507.
[6] 刘家奇, 邵宛芳, 黄业伟, 等. 普洱茶 (熟茶) 茶粉, 黑茶茶粉,六堡茶对非酒精性脂肪肝大鼠肝细胞 CYP2E1 表达的影响[J]. 胃肠病学, 2013, 18(7): 411-415.
[7] 于红艳, 张松筠, 周晓映, 等. 阿卡波糖, 二甲双胍, 吡格列酮对非酒精性脂肪性肝病大鼠肝组织肿瘤坏死因子-α 及细胞色素 P4502E1 的影响[J]. 中国药业, 2013, 22(7): 11-14.
[8] Schiöth H B, Boström A, Murphy S K, et al. A targeted analysis reveals relevant shifts in the methylation and transcription of genes responsible for bile acid homeostasis and drug metabolism in non-alcoholic fatty liver disease[J]. BMC genomics, 2016, 17(1): 462.
[9] 张传涛, 周道杰, 周显华, 等. 加味楂曲饮对实验性非酒精性脂肪肝大鼠 FFA-CYP2E1-MDA 路径的影响[J]. 时珍国医国药, 2014, 25(3): 525-528.
[10] Li Y, Hai J, Li L, et al. Administration of ghrelin improves inflammation,oxidative stress, and apoptosis during and after non-alcoholic fatty liver disease development[J]. Endocrine, 2013, 43(2): 376-386.
[11] 隋晓丹, 邓厚波, 刘铁军. 中医药防治非酒精性脂肪肝病的研究进展[J]. 世界华人消化杂志, 2013, 21(18): 1708.
[12] Berlanga A, Guiu-Jurado E, Porras J A, et al. Molecular pathways in non-alcoholic fatty liver disease[J]. Clin Exp Gastroenterol, 2014, 7(1): 221-239.
[13] Kanuri G, Bergheim I. In vitro and in vivo models of non-alcoholic fatty liver disease (NAFLD)[J]. International journal of molecular sciences, 2013, 14(6): 11963-11980.
[14] 卞晓岚, 沈龙海, 余自成, 等. 降脂利肝颗粒对小鼠急性肝损伤的保护作用[J]. 药学服务与研究, 2008, 8(5): 340-342.
[15] 叶汉章, 翟晨刚, 闵暘. 降脂利肝颗粒对四氯化碳引起小鼠急性肝损伤的保护作用[J]. 中国药理通讯, 2004, 12(3):22.
[16] 余辉, 陈小琳, 王佐兵, 等. 二甲双胍对非酒精性脂肪肝大鼠肝细胞 CYP2E1 表达的影晌[J]. 医学研究杂志, 2013, 42(10): 92-96.
[17] Lin C W, Zhang H, Li M, et al. Pharmacological promotion of autophagy alleviates steatosis and injury in alcoholic and non-alcoholic fatty liver conditions in mice[J]. Journal of hepatology, 2013, 58(5): 993-999.